Switch theme
Sign up to access all valuation multiples
Wuhan Keqian Biology Co Ltd is engaged in research and development, production, sales and animal epidemic prevention technical services of veterinary biological products. The company's products include Combination plan; Vaccine for swine; Poultry vaccine; Pet vaccine; and Diagnostic reagent.
2001
n/a
LTM Revenue $143M
LTM EBITDA $71.3M
$923M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Keqian Biology has a last 12-month revenue (LTM) of $143M and a last 12-month EBITDA of $71.3M.
In the most recent fiscal year, Keqian Biology achieved revenue of $131M and an EBITDA of $76.7M.
Keqian Biology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Keqian Biology valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $143M | XXX | $131M | XXX | XXX | XXX |
| Gross Profit | $93.4M | XXX | $83.4M | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 64% | XXX | XXX | XXX |
| EBITDA | $71.3M | XXX | $76.7M | XXX | XXX | XXX |
| EBITDA Margin | 50% | XXX | 59% | XXX | XXX | XXX |
| EBIT | $65.3M | XXX | $51.0M | XXX | XXX | XXX |
| EBIT Margin | 46% | XXX | 39% | XXX | XXX | XXX |
| Net Profit | $56.9M | XXX | $53.1M | XXX | XXX | XXX |
| Net Margin | 40% | XXX | 41% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Keqian Biology 's stock price is CNY 17 (or $2).
Keqian Biology has current market cap of CNY 7.9B (or $1.1B), and EV of CNY 6.6B (or $923M).
See Keqian Biology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $923M | $1.1B | XXX | XXX | XXX | XXX | $0.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Keqian Biology has market cap of $1.1B and EV of $923M.
Keqian Biology 's trades at 7.1x EV/Revenue multiple, and 12.0x EV/EBITDA.
Equity research analysts estimate Keqian Biology 's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Keqian Biology has a P/E ratio of 19.4x.
See valuation multiples for Keqian Biology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV (current) | $923M | XXX | $923M | XXX | XXX | XXX |
| EV/Revenue | 6.4x | XXX | 7.1x | XXX | XXX | XXX |
| EV/EBITDA | 12.9x | XXX | 12.0x | XXX | XXX | XXX |
| EV/EBIT | 14.1x | XXX | 18.1x | XXX | XXX | XXX |
| EV/Gross Profit | 9.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 19.4x | XXX | 20.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 23.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKeqian Biology 's last 12 month revenue growth is 20%
Keqian Biology 's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Keqian Biology 's rule of 40 is 74% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Keqian Biology 's rule of X is 100% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Keqian Biology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 50% | XXX | 59% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | -1% | XXX | XXX | XXX |
| Rule of 40 | 74% | XXX | 79% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 100% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Keqian Biology acquired XXX companies to date.
Last acquisition by Keqian Biology was XXXXXXXX, XXXXX XXXXX XXXXXX . Keqian Biology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Keqian Biology founded? | Keqian Biology was founded in 2001. |
| Where is Keqian Biology headquartered? | Keqian Biology is headquartered in China. |
| Is Keqian Biology publicy listed? | Yes, Keqian Biology is a public company listed on SHG. |
| What is the stock symbol of Keqian Biology ? | Keqian Biology trades under 688526 ticker. |
| When did Keqian Biology go public? | Keqian Biology went public in 2020. |
| Who are competitors of Keqian Biology ? | Similar companies to Keqian Biology include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Keqian Biology ? | Keqian Biology 's current market cap is $1.1B |
| What is the current revenue of Keqian Biology ? | Keqian Biology 's last 12 months revenue is $143M. |
| What is the current revenue growth of Keqian Biology ? | Keqian Biology revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Keqian Biology ? | Current revenue multiple of Keqian Biology is 6.4x. |
| Is Keqian Biology profitable? | Yes, Keqian Biology is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Keqian Biology ? | Keqian Biology 's last 12 months EBITDA is $71.3M. |
| What is Keqian Biology 's EBITDA margin? | Keqian Biology 's last 12 months EBITDA margin is 50%. |
| What is the current EV/EBITDA multiple of Keqian Biology ? | Current EBITDA multiple of Keqian Biology is 12.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
